Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular
Free webinar: Telepathology: is there added value in LMICs?
Free webinar: Telepathology: is there added value in LMICs?

Therapy of Ph-positive adult ALL

Prof Oliver Ottmann - Cardiff University, Cardiff, UK
Therapy of Ph-positive adult ALL ( Prof Oliver Ottmann - Cardiff University, Cardiff, UK )
23 Jan 2020

The role of blinatumomab followed by HSCT in paediatric patients with ALL

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
The role of blinatumomab followed by HSCT in paediatric patients with ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
23 Jan 2020

Defining the role of immunotherapy in B-cell ALL

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
Defining the role of immunotherapy in B-cell ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
23 Jan 2020

Long-term toxicities in paediatric ALL

Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark
Long-term toxicities in paediatric ALL ( Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark )
23 Jan 2020

How is minimal residual disease managed in patients with ALL?

Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
How is minimal residual disease managed in patients with ALL? ( Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy )
23 Jan 2020

BLAST: Blinatumomab for minimal residual disease in patients with ALL

Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
BLAST: Blinatumomab for minimal residual disease in patients with ALL ( Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy )
23 Jan 2020

Frontline therapy of ALL

Prof Hervé Dombret - University Paris Diderot, Paris, France
Frontline therapy of ALL ( Prof Hervé Dombret - University Paris Diderot, Paris, France )
23 Jan 2020

BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL

Prof Hervé Dombret - University Paris Diderot, Paris, France
BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL ( Prof Hervé Dombret - University Paris Diderot, Paris, France )
23 Jan 2020

Treatment of Ph-negative ALL in adolescents and young adults

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
Treatment of Ph-negative ALL in adolescents and young adults ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jan 2020

The new era of ALL treatment

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
The new era of ALL treatment ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jan 2020

Safety considerations for inotuzumab in patients with relapsed/refractory ALL

Prof David Marks - University Hospitals Bristol NHS Foundation Trust, Bristol, UK
Safety considerations for inotuzumab in patients with relapsed/refractory ALL ( Prof David Marks - University Hospitals Bristol NHS Foundation Trust, Bristol, UK )
23 Jan 2020

HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer

Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA
HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer ( Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA )
23 Jan 2020

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation